tiprankstipranks
Trending News
More News >
Can-Fite BioPharma Ltd (CANF)
:CANF
Advertisement

Can-Fite BioPharma (CANF) Price & Analysis

Compare
586 Followers

CANF Stock Chart & Stats


Can-Fite BioPharma News

CANF FAQ

What was Can-Fite BioPharma Ltd’s price range in the past 12 months?
Can-Fite BioPharma Ltd lowest stock price was $0.63 and its highest was $3.12 in the past 12 months.
    What is Can-Fite BioPharma Ltd’s market cap?
    Can-Fite BioPharma Ltd’s market cap is $14.14M.
      When is Can-Fite BioPharma Ltd’s upcoming earnings report date?
      Can-Fite BioPharma Ltd’s upcoming earnings report date is Nov 21, 2025 which is in 76 days.
        How were Can-Fite BioPharma Ltd’s earnings last quarter?
        Can-Fite BioPharma Ltd released its earnings results on Aug 28, 2025. The company reported -$0.144 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.034.
          Is Can-Fite BioPharma Ltd overvalued?
          According to Wall Street analysts Can-Fite BioPharma Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Can-Fite BioPharma Ltd pay dividends?
            Can-Fite BioPharma Ltd does not currently pay dividends.
            What is Can-Fite BioPharma Ltd’s EPS estimate?
            Can-Fite BioPharma Ltd’s EPS estimate is -0.14.
              How many shares outstanding does Can-Fite BioPharma Ltd have?
              Can-Fite BioPharma Ltd has 15,772,915 shares outstanding.
                What happened to Can-Fite BioPharma Ltd’s price movement after its last earnings report?
                Can-Fite BioPharma Ltd reported an EPS of -$0.144 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went same 0%.
                  Which hedge fund is a major shareholder of Can-Fite BioPharma Ltd?
                  Currently, no hedge funds are holding shares in CANF

                  Company Description

                  Can-Fite BioPharma Ltd

                  Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

                  Can-Fite BioPharma (CANF) Earnings & Revenues

                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Lipocine
                  Edesa Biotech
                  Unity Biotechnology
                  Equillium
                  Cingulate Inc

                  Ownership Overview

                  5.05%94.95%
                  Insiders
                  Mutual Funds
                  5.05% Other Institutional Investors
                  94.95% Public Companies and
                  Individual Investors

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis